Competing Trademark Claims Create Legal Complexity for Musk's Neural Technology Company Elon Musk's brain-computer interface venture faces significant intellectual property challenges after the U.S. Patent and Trademark Office declined to advance its applications for two key product identifiers. The regulatory setback stems from earlier trademark filings by an independent technology developer, creating a complex legal landscape for the neural implant company's branding strategy.

Timeline of Competing Applications

The trademark dispute centers around Neuralink's March 2025 applications for "Telepathy" and "Telekinesis" designations, both intended for the company's revolutionary brain-computer interface products. However, computer scientist Wesley Berry had previously submitted applications for identical marks—filing for Telepathy in May 2023 and Telekinesis in August 2024.

Berry, who co-founded Prophetic, a startup developing sleep technology through wearable devices that induce lucid dreaming, filed these applications independently rather than on behalf of his company. Despite declining to provide commentary on the matter, Berry's earlier filing dates give him priority under current trademark law.

Patent Office Rejection Details

Federal trademark officials notified Neuralink in August that their applications could not proceed due to the existing priority claims. The rejection letters specifically referenced Berry's pending applications and noted additional complications from Telepathy Labs, a Florida-based company already holding trademark rights for similar terminology in the interactive technology sector.

This multi-layered conflict demonstrates the complexity of securing intellectual property rights in the rapidly evolving brain-computer interface industry, where companies are racing to establish brand recognition for groundbreaking medical technologies.

Neuralink's Product Development Context

The disputed trademarks relate to Neuralink's flagship technology designed to restore communication abilities for individuals with paralysis. The surgically implanted device captures neural activity, translating brain signals into commands that can operate smartphones, computers, and other digital devices through thought alone.

Musk publicly introduced the Telepathy designation in January 2024 following the company's first successful human implantation. Since then, nine individuals have received the Neuralink device, according to company announcements, marking significant progress in clinical trials for this revolutionary medical technology.

Technical Specifications and Market Applications

Berry's trademark applications describe products as "software that analyzes EEG to decode internal dialogue to control computer or mobile devices." EEG technology uses scalp-mounted electrodes to record brain electrical activity, representing a less invasive approach compared to Neuralink's surgical implant methodology.

This technical differentiation could prove crucial in determining whether consumer confusion would likely occur between competing products, a key factor in trademark dispute resolution.

Legal Framework and Resolution Pathways

The current situation involves "intent-to-use" applications, allowing inventors to reserve trademark rights before commercial deployment. Berry's Telepathy application received acceptance in December 2024, while his Telekinesis application was approved in August 2025, though neither trademark achieves full registration until commercial use is demonstrated.

Federal regulations provide Berry with three years from acceptance to show commercial utilization; failure to do so would result in application abandonment and potentially clear the path for Neuralink's claims.

Strategic Response Options

Neuralink addressed the Telepathy Labs conflict in an August response, arguing that consumer confusion between their medical device and the Florida company's voice technology services would be unlikely. However, the company has not yet responded to Berry's priority claims, which may represent a more significant challenge.

Legal experts suggest several potential resolution strategies for Neuralink. The company could attempt to purchase Berry's trademark rights, negotiate coexistence agreements allowing shared use of the marks, or challenge Berry's applications based on insufficient commercial development.

Industry Expert Analysis

Intellectual property specialists emphasize that trademark disputes often hinge on likelihood of consumer confusion between competing products. The determination involves analyzing whether average consumers would mistakenly believe different products originate from the same company.

"The advantage currently lies with the earlier applicant," notes trademark attorney Josh Gerben, highlighting Berry's priority position. The outcome depends on various nuanced factors including product similarity, market overlap, and commercial implementation timelines.

Broader Implications for Neural Technology Branding

This dispute reflects growing competition in the brain-computer interface sector, where companies are developing similar technologies for medical and consumer applications. As the industry matures, trademark conflicts may become increasingly common as firms seek memorable branding for revolutionary products.

The case also illustrates challenges facing established companies entering markets where individual inventors or smaller firms have already secured intellectual property rights, requiring careful navigation of existing legal landscapes.

Commercial Development Requirements

Berry faces pressure to demonstrate commercial utilization of his trademarked terms within the federal timeline. His company Prophetic focuses on dream enhancement technology rather than the medical applications Neuralink targets, potentially supporting arguments for coexistence agreements.

The distinction between Berry's EEG-based approach and Neuralink's surgical implant methodology could prove significant in resolving consumer confusion concerns while allowing both parties to maintain their respective market positions.

Future Market Dynamics

The resolution of this trademark dispute will likely influence how neural technology companies approach intellectual property strategy. Early trademark filing, even before product development completion, appears increasingly important for securing brand recognition in this emerging sector.

For Neuralink, the outcome could affect marketing strategies and product positioning as the company prepares for broader commercial deployment of its brain-computer interface technology. The dispute underscores the importance of comprehensive intellectual property planning in rapidly advancing technology sectors.

Regulatory Considerations

Beyond trademark issues, both companies must navigate complex regulatory approval processes for their respective technologies. Neuralink's surgical approach requires extensive FDA oversight, while Berry's external EEG applications may face different regulatory pathways.

The intersection of intellectual property law and medical device regulation creates additional complexity for companies developing neural interface technologies, requiring coordination between legal strategy and regulatory compliance efforts.